Literature DB >> 25165873

Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century.

John P Hutchinson1, Tricia M McKeever, Andrew W Fogarty, Vidya Navaratnam, Richard B Hubbard.   

Abstract

RATIONALE: Evidence from the United Kingdom suggests that the number of deaths from idiopathic pulmonary fibrosis is increasing, although comparable international data are limited.
OBJECTIVES: We aimed to collate death certification data from multiple countries to determine global trends in mortality from idiopathic pulmonary fibrosis.
METHODS: Data were obtained from the national statistics agencies of countries with relevant mortality records. Age-standardized mortality rates were calculated, and Poisson regression modeling was used to calculate rate ratios. Meta-analysis was used to calculate an overall estimate of mortality change over time.
MEASUREMENTS AND MAIN RESULTS: Ten countries provided mortality data on pulmonary fibrosis over a period from 1999 to 2012. Age-standardized mortality ranged between 4 and 10 per 100,000 population for the most recent years of data, being lowest in Sweden (4.68 per 100,000), Spain (5.38 per 100,000), and New Zealand (5.55 per 100,000), and highest in the United Kingdom (9.84 per 100,000 in England and Wales, 10.71 per 100,000 in Scotland) and Japan (10.26 per 100,000). Positive associations with male sex and increasing age were consistently observed across all countries. There was an overall 2-3% annual increase in mortality depending on codes used for classification: For broad codes the overall rate ratio was 1.03 (95% confidence interval, 1.02-1.04; P < 0.001) and for narrow codes the overall rate ratio was 1.02 (95% confidence interval, 1.01-1.03; P < 0.001). Validation in a local cohort showed that idiopathic pulmonary fibrosis was recorded as the underlying cause of death in two-thirds of known cases and anywhere on the death certificate in 80% of cases.
CONCLUSIONS: Mortality from idiopathic pulmonary fibrosis is increasing steadily worldwide, despite the fact that death certification will almost certainly underestimate true mortality. We estimate that there will be between 28,000 and 65,000 deaths in Europe and between 13,000 and 17,000 deaths in the United States from idiopathic pulmonary fibrosis clinical syndrome in 2014. Variation between countries remains but is less than previously reported.

Entities:  

Keywords:  epidemiology; idiopathic pulmonary fibrosis; mortality rates

Mesh:

Year:  2014        PMID: 25165873     DOI: 10.1513/AnnalsATS.201404-145OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  69 in total

Review 1.  Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis.

Authors:  Ana L Mora; Marta Bueno; Mauricio Rojas
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

2.  High-Attenuation Areas on Chest Computed Tomography and Clinical Respiratory Outcomes in Community-Dwelling Adults.

Authors:  Anna J Podolanczuk; Elizabeth C Oelsner; R Graham Barr; Elana J Bernstein; Eric A Hoffman; Imaani J Easthausen; Karen Hinckley Stukovsky; Arindam RoyChoudhury; Erin D Michos; Ganesh Raghu; Steven M Kawut; David J Lederer
Journal:  Am J Respir Crit Care Med       Date:  2017-12-01       Impact factor: 21.405

Review 3.  Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways.

Authors:  Christopher M Evans; Tasha E Fingerlin; Marvin I Schwarz; David Lynch; Jonathan Kurche; Laura Warg; Ivana V Yang; David A Schwartz
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

Review 4.  Idiopathic pulmonary fibrosis in East Asian.

Authors:  Changbo Sun; Yanbin Sun; Hui Shen; Chunlu Yang; Shun Xu
Journal:  Intractable Rare Dis Res       Date:  2017-05

5.  Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.

Authors:  Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

Review 6.  Idiopathic Pulmonary Fibrosis Is a Genetic Disease Involving Mucus and the Peripheral Airways.

Authors:  David A Schwartz
Journal:  Ann Am Thorac Soc       Date:  2018-11

Review 7.  The role of periostin in lung fibrosis and airway remodeling.

Authors:  David N O'Dwyer; Bethany B Moore
Journal:  Cell Mol Life Sci       Date:  2017-09-16       Impact factor: 9.261

8.  Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Authors:  Simon L F Walsh; Toby M Maher; Martin Kolb; Venerino Poletti; Richard Nusser; Luca Richeldi; Carlo Vancheri; Margaret L Wilsher; Katerina M Antoniou; Jüergen Behr; Elisabeth Bendstrup; Kevin Brown; Lucio Calandriello; Tamera J Corte; Vincent Cottin; Bruno Crestani; Kevin Flaherty; Ian Glaspole; Jan Grutters; Yoshikazu Inoue; Maria Kokosi; Yasuhiro Kondoh; Vasileios Kouranos; Michael Kreuter; Kerri Johannson; Eoin Judge; Brett Ley; George Margaritopoulos; Fernando J Martinez; Maria Molina-Molina; António Morais; Hilario Nunes; Ganesh Raghu; Christopher J Ryerson; Moises Selman; Paolo Spagnolo; Hiroyuki Taniguchi; Sara Tomassetti; Dominique Valeyre; Marlies Wijsenbeek; Wim Wuyts; David Hansell; Athol Wells
Journal:  Eur Respir J       Date:  2017-08-31       Impact factor: 16.671

9.  African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Shashi K Bellam; Jonathan H Chung; Paul A Chung; Kathleen M Biblowitz; Steven Montner; Cathryn Lee; Scully Hsu; Aliya N Husain; Rekha Vij; Gokhan Mutlu; Imre Noth; Matthew M Churpek; Mary E Strek
Journal:  Eur Respir J       Date:  2018-06-14       Impact factor: 16.671

10.  Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.

Authors:  Hongmei Gu; Amanda J Fisher; Elizabeth A Mickler; Frank Duerson; Oscar W Cummings; Marc Peters-Golden; Homer L Twigg; Trent M Woodruff; David S Wilkes; Ragini Vittal
Journal:  FASEB J       Date:  2016-03-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.